Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.
Profitability
This table compares Madrigal Pharmaceuticals and VYNE Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Madrigal Pharmaceuticals | N/A | -219.39% | -98.75% |
VYNE Therapeutics | -6,710.38% | -77.46% | -62.93% |
Insider and Institutional Ownership
98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 23.9% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Madrigal Pharmaceuticals and VYNE Therapeutics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Madrigal Pharmaceuticals | 1 | 1 | 9 | 0 | 2.73 |
VYNE Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Madrigal Pharmaceuticals presently has a consensus target price of $351.45, indicating a potential upside of 69.85%. VYNE Therapeutics has a consensus target price of $7.38, indicating a potential upside of 178.30%. Given VYNE Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe VYNE Therapeutics is more favorable than Madrigal Pharmaceuticals.
Valuation and Earnings
This table compares Madrigal Pharmaceuticals and VYNE Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Madrigal Pharmaceuticals | N/A | N/A | -$373.63 million | ($19.94) | -10.38 |
VYNE Therapeutics | $420,000.00 | 88.96 | -$28.45 million | ($7.04) | -0.38 |
VYNE Therapeutics has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
VYNE Therapeutics beats Madrigal Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.